| Released | Contributor | Author | Title | Pages | Price |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ANDS | 13 |
$25 |
| 8-Feb-2010 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 6-Feb-2010 | Standard & Poor's Quantitative Report |
N/A
| Anadys Pharmaceuticals | 6 |
$25 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | ANADYS PHARMACEUTICALS INC (ANDS=US) 2-weeks forecast | 1 |
$10 |
| 5-Feb-2010 | Pechala's Reports | Frantisek Pechala | ANADYS PHARMACEUTICALS INC (ANDS=US) 12-months forecast | 1 |
$15 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: ANADYS PHARMACEU -- ANDS | 1 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACOR , AFFY , ANDS , BSTC , OMPI , TELK -- DRUGS | 3 |
$4 |
| 4-Feb-2010 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ANADYS PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 11 |
$20 |
| 4-Feb-2010 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Anadys Pharmaceuticals, Inc. | 40 |
$65 |
1.52% Nasdaq 0.00%
Research Reports
